Understanding T cells in MOG Antibody-Associated Disease
Characterization of T cells in MOG antibody-associated disease
This research aims to understand how certain immune cells, called T cells, contribute to a group of autoimmune conditions known as MOG antibody-associated disease (MOGAD).
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11094890 on NIH RePORTER |
What this research studies
MOG antibody-associated disease (MOGAD) is a group of autoimmune conditions affecting the brain and spinal cord, including optic neuritis and transverse myelitis. Currently, there are no specific treatments approved for MOGAD. This project focuses on the role of T cells, a type of immune cell, which are believed to work with other immune cells (B cells) and antibodies to cause damage in the central nervous system. Researchers believe that B cells might present specific signals to T cells, leading to the development of harmful T cells. By studying these interactions, we hope to uncover new ways to target the disease process.
Who could benefit from this research
Good fit: Patients diagnosed with MOG antibody-associated disease (MOGAD), including those with acute disseminated encephalomyelitis, optic neuritis, or transverse myelitis, are the focus of this research.
Not a fit: Patients without MOGAD or other autoimmune conditions affecting the central nervous system may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to a better understanding of MOGAD and help develop new, targeted treatments for patients living with this autoimmune condition.
How similar studies have performed: While MOG-induced EAE models are established for studying MOGAD, the specific focus on B cell antigen presentation and its impact on the T cell repertoire in MOGAD pathogenesis represents a novel area of investigation.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Zamvil, Scott S — University of California, San Francisco
- Study coordinator: Zamvil, Scott S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.